Evidence map›Paper›PMID 39417339›Full record

ArticleFuture oncology (London, England)2024

The clinical utility of plasma circulating tumor DNA in the diagnosis and disease surveillance in non-diffuse large B-cell non-Hodgkin lymphomas.

Xiaoping Zhang, Li Yang, Minyi Zhu, Xiaotian Zhao, Yao Xiao, Jiaohui Pang, Liuqing Zhu, Qiuxiang Ou, Hai-Wen Ni, Jingyan Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaoping ZhangHematology Department, Zhongda Hospital, Southeast University, Nanjing, China.ORCID 0009-0002-9497-9231
Li YangDepartment of Hematology, Affiliated Hospital of Nantong University, Nantong, China.
Minyi ZhuGeneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing, China.ORCID 0009-0005-7440-3026
Xiaotian ZhaoGeneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing, China.ORCID 0000-0003-3823-3232
Yao XiaoGeneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing, China.
Jiaohui PangGeneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing, China.
Liuqing ZhuGeneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing, China.
Qiuxiang OuGeneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing, China.ORCID 0000-0002-2961-2057
Hai-Wen NiDepartment of Hematology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Jingyan XuDepartment of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.ORCID 0000-0002-4093-855X

Funding

National Health Commission Medical and Health Science and Technology Development Research Center Post-Marketing Clinical Research Special Project for Innovative Drugs WKZX2023CX020008National Natural Science Foundation of China 82300151Xinrui Tumor Support Therapy Project Fund FB2024012256
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Biomarkers, TumorCirculating Tumor DNAAdultAgedAged, 80 and overFemaleHigh-Throughput Nucleotide SequencingHumansLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMaleMiddle AgedMutationRetrospective StudiesBiomarkers, TumorCirculating Tumor DNAcirculating tumor DNAconcordancenon-Hodgkin lymphomaplasma biopsy

Identifiers

PMID39417339
PMCPMC13179002

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.